The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Nektar Therapeutics beat expectations on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue grew significantly. GAAP loss per share grew.
Gross margins were steady, operating margins increased, net margins contracted.
Nektar Therapeutics logged revenue of $21.1 million. The nine analysts polled by S&P Capital IQ expected revenue of $19.1 million on the same basis. GAAP reported sales were 34% higher than the prior-year quarter's $15.8 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.46. The six earnings estimates compiled by S&P Capital IQ predicted -$0.46 per share. GAAP EPS were -$0.46 for Q4 compared to -$0.33 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 65.5%, much about the same as the prior-year quarter. Operating margin was -205.1%, much better than the prior-year quarter. Net margin was -250.3%, much worse than the prior-year quarter.
Next quarter's average estimate for revenue is $26.9 million. On the bottom line, the average EPS estimate is -$0.38.
Next year's average estimate for revenue is $177.1 million. The average EPS estimate is -$0.91.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 199 members out of 230 rating the stock outperform, and 31 members rating it underperform. Among 58 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 45 give Nektar Therapeutics a green thumbs-up, and 13 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Nektar Therapeutics is outperform, with an average price target of $11.29.
- Add Nektar Therapeutics to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.